Lithium treatment

PreclinicalSmall molecule

VVA Office of Research and Development

Lithium treatment is one of 99 small molecule programs targeting Bipolar I Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar I DisorderActive, not recruiting

Cognitive DisorderActive, not recruiting

Bipolar DisorderActive, not recruiting

Bipolar I DisorderPreclinical

Active, not recruiting

Cognitive DisorderPhase 1/Phase 2

Active, not recruiting

Bipolar DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

192 competitors in Bipolar Disorder

#DrugCompanyPhaseTrials

Depacon

AbbVie

Phase 3

6 2

Depakote

AbbVie

Phase 3

5 3

Depakote

AbbVie

Phase 3

5 4

Robitussin

Pfizer

Phase 3

2 5

Lexapro

AbbVie

Phase 3

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

3 7

Ketalar

Boehringer Ingelheim

Phase 3

2 8

Methylthioninium Chloride

PProvepharm SAS

Phase 3

1 9

Rescue

Merck & Co.

Phase 3

2 10

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Cognitive Disorder

NCT06776848

Clinical

Trials by Indication[1]

Cognitive Disorder1 trial

A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder

Recruiting·—·Phase 1/2·NCT06776848·12 enrolled

Bipolar I Disorder1 trial

Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT04209140·320 enrolled

Bipolar Disorder1 trial

Genetic Predictors of Lithium Response in Bipolar Disorder

Completed·VVA Office of Research and Development··NCT00252577·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lithium treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lithium treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lithium treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVA Office of Research and Development

Lithium treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cognitive Disorder1 trial

Bipolar I Disorder1 trial

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News